CurrentBlue Cross Blue Shield - New MexicoPolicy CPCPLABO64

Nerve Fiber Density Testing (skin biopsy for epidermal nerve fiber density)

BCBSNM clinical payment and coding policy governing reimbursement criteria for skin biopsy with epidermal nerve fiber density measurement for diagnosis of small-fiber neuropathy and exclusion of sweat gland nerve fiber density measurement. Applies to plan products where covered; providers should review specific plan documents.

Policy Summary

PayerBlue Cross Blue Shield - New Mexico

PolicyNerve Fiber Density Testing (skin biopsy for epidermal nerve fiber density)

Policy CodePolicy CPCPLABO64

Change TypeRevised (7/5/2023)Added (11/1/2022)

Effective DateSep 1, 2023

Next Review Date

Key ActionProviders must document symptoms of painful sensory neuropathy, absence of history predisposing to painful neuropathy, physical exam findings excluding large-fiber neuropathy, and normal EMG/nerve conduction studies to support reimbursement.

SourceLink

POLICY UPDATE CHANGES

Document updated with literature review and reimbursement information revised on 7/5/2023.

New policy created 11/1/2022 (initial version).

1Policy Version

ENFD onlyReimbursable Test Type

Sweat gland densityNot Reimbursable Test Type

Policy summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Policy Number: CPCPLABO64; Subject: Nerve Fiber Density Testing (skin biopsy for epidermal nerve fiber density); Status: CURRENT (effective 2023-09-01; last reviewed 2023-07-05).

Scope: This BCBSNM clinical payment and coding policy governs reimbursement criteria for skin biopsy with measurement of epidermal nerve fiber density (ENFD) used to diagnose small-fiber neuropathy. It applies to plan products where covered; providers should review specific plan documents as plan documents or provider contracts govern in cases of conflict.

Coverage summary: Skin biopsy with ENFD measurement may be reimbursable for the diagnosis of small-fiber neuropathy when specified clinical criteria are met (see reimbursement criteria). The policy explicitly excludes measurement of sweat gland nerve fiber density and does not reimburse ENFD for monitoring disease progression or response to treatment.

Clinical intent: The policy supports use of ENFD skin biopsy as a diagnostic test for patients presenting with symptoms of painful sensory neuropathy when other causes are excluded and large-fiber neuropathy has been ruled out by exam and electrodiagnostic testing. Providers must document clinical presentation, absence of predisposing disorders, physical examination findings, and normal EMG/nerve conduction studies to support reimbursement.

Policy metadata (high-level) - CPCPLABO64

Policy NumberCPCPLABO64

Effective Date2023-09-01

Last Review2023-07-05

Next Review

Policy Version1

Reimbursable Test TypeENFD only

Not Reimbursable Test TypeSweat gland density

Coverage Stancebilling_rules

Scope SummaryBCBSNM clinical payment and coding policy governing reimbursement criteria for skin biopsy with epidermal nerve fiber density measurement for diagnosis of small-fiber neuropathy and exclusion of sweat gland nerve fiber density measurement. Applies to plan products where covered; providers should review specific plan documents.

Reimbursement criteria and exclusions

Reimbursement criteria for epidermal nerve fiber density (ENFD) measurement

Reimbursable for the diagnosis of small-fiber neuropathy when ALL of the following are met:

ALL of the following

Symptoms: An individual presents with symptoms of painful sensory neuropathy
No predisposing disorder: There is no history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy)
Physical exam excluding large-fiber neuropathy: Physical examination shows no evidence of findings consistent with large-fiber neuropathy, such as reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation
Electrodiagnostic testing: Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy

ref”: “b1_0

title":

Not reimbursable / Exclusions

Not reimbursable in the following situations:

ANY of the following

Monitoring/response: Monitoring of disease progression or response to treatment (skin biopsy with ENFD measurement is not reimbursable for these indications)
Other conditions: All other conditions not meeting the diagnostic criteria above
Sweat gland measurement: Measurement of sweat gland nerve fiber density is not reimbursable

ref": "b1_1",

Required documentation and billing rules

Documentation Required

Document clinical presentation and prior testing

Providers must document symptoms of painful sensory neuropathy, absence of a history predisposing to painful neuropathy, physical exam findings that exclude large-fiber neuropathy, and normal electromyography/nerve conduction studies to support reimbursement for epidermal nerve fiber density testing.

Symptoms of painful sensory neuropathy
Absence of history of a disorder known to predispose to painful neuropathy (e.g., diabetic, toxic, HIV, celiac, inherited neuropathy)
Physical exam findings excluding large-fiber neuropathy (no reduced/absent muscle-stretch reflexes; preserved proprioception and vibration sensation)
Normal electromyography and nerve-conduction studies showing no evidence of large-fiber neuropathy

Billing Rule

Plan-specific coverage may vary

Not all requirements apply to every product. Providers should confirm coverage details with the specific Plan documents for the product under which the member is covered.

Check product-specific plan documents (Certificates of Benefits, benefit booklets, Summary Plan Descriptions, or other coverage documents) for coverage differences

Clinical guidance and evidence

Guideline and evidence summary: Multiple society guidelines and literature (including the American Academy of Neurology, EFNS/Peripheral Nerve Society, and American Diabetes Association) support the diagnostic role of skin biopsy with intra-epidermal/epidermal nerve fiber density measurement in evaluating suspected small-fiber neuropathy.

Rationale for exclusions: Evidence and guideline sources note that quantification of sweat gland innervation is a separate technique and is not included in this policy for reimbursement; similarly, skin biopsy ENFD is intended as a diagnostic tool rather than for routine monitoring of disease progression or treatment response.

Clinical context: The policy reflects guideline-based practice where ENFD complements clinical assessment and normal nerve conduction/EMG when large-fiber neuropathy is not present. Documentation of symptoms, exclusion of disorders known to predispose to painful neuropathy, focused physical exam excluding large-fiber signs, and normal electrodiagnostic studies are required per the policy to justify diagnostic ENFD testing.